This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta

TG Therapeutics' market cap is under $100 million, so the stock looks cheap relative to its P113K competitors. Makes total sense. It's also a bit early to conclude anything about the efficacy and safety of TG-1202 relative to its competitors, most of which are well ahead in clinical trials. Data presented last year by the company showed TG-1202 to be roughly comparable to similar drugs in terms of selectivity to the molecular target. A phase I study of TG-1202 in blood cancers started in January.

I'd be remiss if I didn't also mention the provenance of TG Therapeutics because it will surely give institutional investors with long memories some pause. TG Therapeutics was formerly Manhattan Pharmaceuticals, a Lindsay Rosenwald creation. TG's current CEO is Mike Weiss, a longtime Rosenwald lieutenant who was previously in charge of Keryx Pharmaceuticals (KERX). For every drug out of Rosenwald's stable that shows promise (Keryx's Zerenex) there are many more that end up duds.

It's an issue to think about with respect to TG-1202. Owning a drug in with a hot molecular target is not the same as developing that drug successfully. In the absence of clinical data and in the current bull market, perhaps all that matters is TG Therapeutics' cheap stock relative to its competitors. At least that's what I hear from the biotech trading Twitterati.


@MarvinOLicious tweets, "Do you think $IMUC is hiding something by reporting that of the 278 patients, only 124 qualified to be randomized?"

ImmunoCellular Therapeutics isn't hiding anything but it's silly to talk about 278 patients "enrolled" when, as you said, only 124 were actually randomized into the phase II study of its brain tumor vaccine ICT-107.

The 278 patients represent the total number screened for entry into the trial. Of that, 124 patients were accepted and randomized to ICT-107 or placebo. More than half of screened patients were excluded from the trial because they lacked specific antigens deemed favorable to ICT-107 vaccine.

ImmunoCellular enrolled 124 patients, not 278. Saying otherwise just creates unnecessary confusion. Interim results from the study are expected by the middle of the year, with final results at year's end.


3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,289.82 +23.83 0.14%
S&P 500 2,011.00 -0.36 -0.02%
NASDAQ 4,571.0880 -22.3370 -0.49%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs